Milestone Pharmaceuticals (MIST) Competitors $1.32 +0.01 (+0.38%) Closing price 03:58 PM EasternExtended Trading$1.32 0.00 (0.00%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIST vs. CYRX, ATXS, AQST, AURA, PVLA, ITOS, ACB, CMPX, TSVT, and TERNShould you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Cryoport (CYRX), Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST), Aura Biosciences (AURA), Palvella Therapeutics (PVLA), iTeos Therapeutics (ITOS), Aurora Cannabis (ACB), Compass Therapeutics (CMPX), 2seventy bio (TSVT), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry. Milestone Pharmaceuticals vs. Cryoport Astria Therapeutics Aquestive Therapeutics Aura Biosciences Palvella Therapeutics iTeos Therapeutics Aurora Cannabis Compass Therapeutics 2seventy bio Terns Pharmaceuticals Milestone Pharmaceuticals (NASDAQ:MIST) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability. Do analysts recommend MIST or CYRX? Milestone Pharmaceuticals presently has a consensus target price of $17.00, suggesting a potential upside of 1,187.88%. Cryoport has a consensus target price of $11.67, suggesting a potential upside of 109.08%. Given Milestone Pharmaceuticals' higher possible upside, research analysts plainly believe Milestone Pharmaceuticals is more favorable than Cryoport.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Cryoport 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Does the MarketBeat Community favor MIST or CYRX? Cryoport received 166 more outperform votes than Milestone Pharmaceuticals when rated by MarketBeat users. However, 68.55% of users gave Milestone Pharmaceuticals an outperform vote while only 65.88% of users gave Cryoport an outperform vote. CompanyUnderperformOutperformMilestone PharmaceuticalsOutperform Votes8568.55% Underperform Votes3931.45% CryoportOutperform Votes25165.88% Underperform Votes13034.12% Does the media favor MIST or CYRX? In the previous week, Milestone Pharmaceuticals and Milestone Pharmaceuticals both had 2 articles in the media. Milestone Pharmaceuticals' average media sentiment score of 1.78 beat Cryoport's score of 0.58 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cryoport 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in MIST or CYRX? 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Cryoport shares are owned by institutional investors. 9.9% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 10.1% of Cryoport shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, MIST or CYRX? Milestone Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Is MIST or CYRX more profitable? Milestone Pharmaceuticals has a net margin of 0.00% compared to Cryoport's net margin of -70.08%. Cryoport's return on equity of -13.35% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Milestone PharmaceuticalsN/A -151.82% -49.85% Cryoport -70.08%-13.35%-6.43% Which has preferable valuation and earnings, MIST or CYRX? Milestone Pharmaceuticals has higher earnings, but lower revenue than Cryoport. Cryoport is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMilestone Pharmaceuticals$1M70.43-$59.69M-$0.68-1.94Cryoport$228.39M1.22-$99.59M-$2.49-2.24 SummaryCryoport beats Milestone Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIST vs. The Competition Export to ExcelMetricMilestone PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.43M$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-1.637.4422.5118.48Price / Sales70.43242.70395.68103.60Price / CashN/A65.8538.1834.62Price / Book2.646.516.774.25Net Income-$59.69M$143.21M$3.22B$248.23M7 Day Performance4.76%1.98%1.45%0.89%1 Month Performance73.68%6.89%3.97%3.53%1 Year Performance-17.50%-2.52%16.14%5.08% Milestone Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MISTMilestone Pharmaceuticals1.8843 of 5 stars$1.33+0.4%$17.00+1,183.0%-20.0%$70.69M$1M-1.6430News CoveragePositive NewsGap UpCYRXCryoport2.3918 of 5 stars$5.70-1.0%$11.67+104.7%-65.5%$284.49M$228.39M-1.691,020Upcoming EarningsATXSAstria Therapeutics2.5439 of 5 stars$4.96-4.1%$26.60+436.3%-43.8%$279.91MN/A-2.3730Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageAQSTAquestive Therapeutics1.6579 of 5 stars$2.83-1.4%$10.67+276.9%-13.1%$279.81M$57.56M-6.29160Upcoming EarningsNews CoveragePositive NewsAURAAura Biosciences2.334 of 5 stars$5.51+2.4%$22.75+312.9%-21.2%$276.74MN/A-3.1850Upcoming EarningsShort Interest ↑News CoveragePositive NewsPVLAPalvella Therapeutics3.4225 of 5 stars$24.57-3.2%$44.43+80.8%N/A$270.74M$42.81M-2.03N/AAnalyst ForecastPositive NewsITOSiTeos Therapeutics2.0969 of 5 stars$7.07-3.8%$25.75+264.2%-32.5%$270.03M$35M-2.2490Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsACBAurora Cannabis0.6347 of 5 stars$4.68-2.7%N/A-49.7%$263.08M$320.81M93.621,340News CoverageCMPXCompass Therapeutics3.386 of 5 stars$1.90-2.1%$13.38+603.9%+29.2%$262.74M$850,000.00-5.1320Analyst ForecastShort Interest ↑Analyst RevisionTSVT2seventy bio1.7593 of 5 stars$4.99+0.2%$5.60+12.2%+9.4%$261.17M$37.86M-2.68440Short Interest ↑News CoverageTERNTerns Pharmaceuticals4.2794 of 5 stars$2.94+0.7%$18.38+525.0%-34.7%$256.66MN/A-2.4940Positive News Related Companies and Tools Related Companies CYRX Alternatives ATXS Alternatives AQST Alternatives AURA Alternatives PVLA Alternatives ITOS Alternatives ACB Alternatives CMPX Alternatives TSVT Alternatives TERN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIST) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MIST Stock Free MIST Stock Alerts